121345-64-0
121345-64-0 structure
- Name: SR33805
- Chemical Name: N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine
- CAS Number: 121345-64-0
- Molecular Formula: C32H40N2O5S
- Molecular Weight: 564.73500
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
- Create Date: 2017-10-31 20:27:08
- Modify Date: 2024-02-06 14:30:20
-
SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts[1][2].
| Name | N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine |
|---|---|
| Synonyms |
3,4-Dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)benzeneethanamine
Benzeneethanamine,3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl) N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine |
| Description | SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts[1][2]. |
|---|---|
| Related Catalog | |
| Target |
L-type calcium channel:4.1 nM (EC50, in depolarized conditions) L-type calcium channel:33 nM (EC50, in polarized conditions) |
| In Vitro | SR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.2050<0.46 µM) in a dose-dependent manner[3]. SR33805 (10 µM; 10 min) restores the myocardial infarction (MI)-altered cell shortening without affecting the Ca2+ transient amplitude[2]. SR33805 (10 µM) decreases the activity of recombinant PKA[2]. Cell Viability Assay[3] Cell Line: Smooth muscle cells (SMC) Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 3 days Result: Inhibited in a dose-dependent manner FCS-, bFGF and PDGF-induced proliferation of porcine SMC with IC50s of 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM, respectively. |
| In Vivo | SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats[2]. SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs[3]. Animal Model: Male Wistar rats (5 weeks) are subjected to coronary artery ligature[2] Dosage: 0.2, 2, 20 mg/kg Administration: A single i.p. injection Result: Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters. |
| References |
| Density | 1.15g/cm3 |
|---|---|
| Boiling Point | 724.1ºC at 760mmHg |
| Molecular Formula | C32H40N2O5S |
| Molecular Weight | 564.73500 |
| Flash Point | 391.7ºC |
| Exact Mass | 564.26600 |
| PSA | 78.38000 |
| LogP | 7.17590 |
| Vapour Pressure | 8.05E-21mmHg at 25°C |
| Index of Refraction | 1.57 |